An open, prospective,multicenter,parallel arm,randomized controlled trial to assess the efficacy of beta-block agent for heart failure patients of left ventricle ejection fraction>40%

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000144

Enrollment

Unknown

Registered

2008-08-22

Start date

2008-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure of left ventricle ejection fraction>40%

Interventions

control group:orthodox drug treatment for heart failure, in cluding single or alliance therapy by diuretic agent, ACEI, apresoline, prolonged action nitrate, ARB and cardiotonic glycoside

research group:amber acid metoprolol + orthodox drug treatment for heart failure, in cluding single or alliance therapy by diuretic agent, ACEI, apresoline, prolonged action nitrate, ARB and cardioton

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 40-80 years; 2. Patients with hart failure of NYHA II-IV for more than 3 months; 3. Patients' left ventricle ejection fraction>40%; 4. Patients' NTproBNP>1500pg/ml5.Patients are receiving orthodox drug treatment for heart failure, in cluding single or alliance therapy by diuretic agent, ACEI, apresoline, prolonged action nitrate, ARB and cardiotonic glycoside, for more than 2 weeks when randomization; 6. Patients could be followed up in out-patient clinic; 7. Signed informed consent for the study.

Exclusion criteria

Exclusion criteria: 1. Women of childbearing potrntial without adequate birthcontrol; 2. Unstable angina pectoris or myocardial infarction during the last 28 days; 3. History of sinus bradycardia, heart rate<55 beats per minute; 4. Must be treated by beta-block agent or have the counterindication of beta-block agent 5. Heart failure caused by (1) obstructive hypertrophic cardiomyopathy (cardiomyopathy nonobstructive, include apical hypertrophic cardiomyopathy could be involved); (2) restrictive cardiomyopathy; (3) congenital cardiopathy; (4) Clinically overt primary valvular heart disease can not be retrieved; (5) heart valve prosthesis functional defect; (6) pericardial disease; (7) systemic disease (for example: systemic disease or amyloid degeneration); 6. Traumatic treatment as (1) accepted CABG or PCI during the last 3 months or will accept CABG or PCI in 3 months; (2) implanted ICD or will Implant ICD; (3) accepted heart transplant or will accept heart transplant; 7. History of high degree atrio-ventricular block(second degree A-V block, third A-V block or sick sinus syndrome), unless the patient has been implanted pacemaker; 8. Unstable decompensation heart failure by adequate treatment,or occured hypotension (Bp<90/60mmHg, concomitant the symptom of dizziness, cold clammy limbs, diaphoresis and so on) at the time of randomization; 9. Any other serious diseases such as: (1) HIV infection; (2) malignant tumor; (3) overt primary Liver disease or Kidney disease; (4) alcohol or drug abuse; (5) bad compliance; 10. Previous (30 preceding days) or current participation another clinical trial.

Design outcomes

Primary

Measure	Time frame
deaths total rate;associate rate of hospitalization and death;	—

Secondary

Measure	Time frame
ejection fraction and heart function(classed by NY;	—

Countries

China

Contacts

Public ContactJunbo Ge

ge.junbo@zs-hospital.sh.cn+86 64041990-2745

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026